Shenogen Announces a New Member to Scientific Advisory Board: Dr. Genhong Cheng


Oct 10th, 2015, Beijing, China


Shenogen Pharma Group announces the addition of Dr. Genhong Cheng to its Scientific Advisory Board (SAB). Dr. Genhong Cheng is President of Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences (CAMS) and professor in Department of Microbiology, Immunology and Molecular Genetics at UCLA.


“We are delighted to welcome Dr. Cheng to our SAB.” said Dr. Kun Meng, Chairman & CEO of Shenogen. “Dr. Cheng is has 20-year experience and significant contribution in inflammatory and cancer immunology research. We are sure that his advice will be helpful for us making better decision of development direction and future strategy.” Dr. Cheng regards Shenogen as to be a leading biopharma company in China with innovative technology and cancer target. He appreciates the encouraging clinical results of icaritin and hopes to help in discovering further mechanism of icaritin in cancer treatment.


Dr. Cheng starts his research in the fields of infection, immunology, oncology and metabolism since 1996. He was awarded a lot for his excellent scientific work and selected as AAAS member. Dr. Cheng got over 20 grants from institutes including NIH and published more than 140 papers on top journals. He was selected into Changjiang Scholars Program in 2009 and National Recruitment Program of Global Experts in 2012. He joined Center of System Medicine, CAMS as director. Dr. Cheng received Ph.D degree in Molecular Biology from Albert Einstein College of Medicine, and worked as postdoctoral fellow at Rockefeller University and MIT.


Dr. Cheng joins Drs. Michael Karin, Douglas Hanahan, V. Craig Jordan, Robert N. Eisenman, Yan Sun and Changxiao Liu who are currently members of Shenogen’s Scientific Advisory Board.


About Shenogen

Shenogen Pharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently completing Ph II clinical trial for treatment of advanced hepatocellular carcinoma.

(For more information, please visit


Shenogen Announces a New Member to Scientific Advisory Board: Dr. Genhong Cheng